Prognostic and symptomatic aspects of rapid eye movement sleep in a mouse model of posttraumatic stress disorder

• Main Authors: Stephanie A. Polta, Thomas eFenzl, Vladimira eJakubcakova, Mayumi eKimura, Alexander eYassouridis, Carsten T. Wotjak
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2013-05-01
• Series: Frontiers in Behavioral Neuroscience
• Subjects: Fear conditioning; biomarker; PTSD; sleep fragmentation; animal model; REM sleep
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fnbeh.2013.00060/full

Not every individual develops Posttraumatic Stress Disorder (PTSD) after the exposure to a potentially traumatic event. Therefore, the identification of pre-existing risk factors and early diagnostic biomarkers is of high medical relevance. However, no objective biomarker has yet progressed into clinical practice. Sleep disturbances represent commonly reported complaints in PTSD patients. In particular, changes in rapid eye movement sleep (REMS) properties are frequently observed in PTSD patients. Here, we examined in a mouse model of PTSD whether (1) mice developed REMS alterations after trauma and (2) whether REMS architecture before and/or shortly after trauma predicted the development of PTSD-like symptoms. We monitored sleep-wake behavior via combined EEG/EMG recordings immediately before (24 h pre), immediately after (0-48 h post) and two months after exposure to an electric foot shock in male C57BL/6N mice (n=15). PTSD-like symptoms, including hyperarousal, contextual and generalized fear, were assessed one month post-trauma.Shocked mice showed early-onset and sustained elevation of REMS compared to non-shocked controls. In addition, REMS architecture before trauma was correlated with the intensity of acoustic startle responses, but not contextual fear, one month after trauma.Our data suggest REMS as prognostic (pre-trauma) and symptomatic (post-trauma) marker of PTSD-like symptoms in mice. Translated to the situation in humans, REMS may constitute a viable, objective and non-invasive biomarker in PTSD and other trauma-related psychiatric disorders, which could guide pharmacological interventions in humans at high risk.